{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T06:34:15Z","timestamp":1648622055677},"reference-count":44,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Most people with mantle cell lymphoma (MCL) present with diffuse adenopathy and benefit from early initiation of rituximab and high-dose cytarabine- or bendamustine-based therapies. Some patients, however, present with primarily nonnodal disease that can follow either an indolent or a rapidly progressive, treatment-resistant clinical course. Rarely, patients present with explosive disease that can be challenging to manage and often involves the central nervous system. New agents with improved therapeutic indices facilitate treatment while maintaining quality of life, but also present new complications at the time of treatment failure. Although uncommon presentations are not new to clinicians who treat MCL, the increasing clarity of underlying biology and prognostic implications may help us develop more specialized treatment strategies.<\/jats:p>","DOI":"10.1182\/asheducation-2017.1.304","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T18:13:11Z","timestamp":1555438391000},"page":"304-309","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Optimizing therapy for mantle cell lymphoma"],"prefix":"10.1182","volume":"2017","author":[{"given":"Peter","family":"Martin","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology-Medical Oncology, Weill Cornell Medicine, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"10044","key":"2019111703273082300_B1","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"2019111703273082300_B2","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"issue":"9873","key":"2019111703273082300_B3","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"suppl 3","key":"2019111703273082300_B4","doi-asserted-by":"crossref","first-page":"iii83","DOI":"10.1093\/annonc\/mdu264","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Dreyling","year":"2014","journal-title":"Ann Oncol"},{"key":"2019111703273082300_B5","article-title":"Clinical Practice Guidelines in Oncology - B-cell lymphomas v3.2017","author":"National Comprehensive Cancer Network","year":"2017"},{"issue":"8","key":"2019111703273082300_B6","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J Clin Oncol"},{"issue":"32","key":"2019111703273082300_B7","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1200\/JCO.2009.23.9731","article-title":"Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma","volume":"27","author":"Eve","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111703273082300_B8","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood-2014-03-559930","article-title":"Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study","volume":"124","author":"Abrahamsson","year":"2014","journal-title":"Blood"},{"issue":"15","key":"2019111703273082300_B9","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1002\/cncr.30068","article-title":"Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma","volume":"122","author":"Cohen","year":"2016","journal-title":"Cancer"},{"issue":"4","key":"2019111703273082300_B10","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3109\/10428194.2013.815353","article-title":"Indolent mantle cell lymphoma","volume":"55","author":"Hsi","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"20","key":"2019111703273082300_B11","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","article-title":"Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features","volume":"72","author":"Navarro","year":"2012","journal-title":"Cancer Res"},{"issue":"8","key":"2019111703273082300_B12","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1038\/leu.2012.72","article-title":"Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease","volume":"26","author":"Royo","year":"2012","journal-title":"Leukemia"},{"issue":"45","key":"2019111703273082300_B13","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Be\u00e0","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"2019111703273082300_B14","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network","volume":"34","author":"Hoster","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111703273082300_B15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12308-009-0036-x","article-title":"Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network","volume":"2","author":"Klapper","year":"2009","journal-title":"J Hematop"},{"issue":"3","key":"2019111703273082300_B16","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"issue":"22","key":"2019111703273082300_B17","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood.V128.22.1095.1095","article-title":"Targeted sequencing of diagnostic samples correlated to clinical outcome: data from the Nordic Mantle Cell Lymphoma (MCL2 and MCL3) Studies with long-term follow-up","volume":"128","author":"Eskelund","year":"2016","journal-title":"Blood"},{"issue":"23","key":"2019111703273082300_B18","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/blood.V126.23.336.336","article-title":"A molecular model for the prediction of progression free survival in young mantle cell lymphoma patients treated with cytarabine-based high dose sequential chemotherapy and autologous stem cell transplantation: results from the MCL0208 phase III trial from Fondazione Italiana Linfomi (FIL)","volume":"126","author":"Rossi","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2019111703273082300_B19","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2011.162","article-title":"Impact of TP53 mutation and 17p deletion in mantle cell lymphoma","volume":"25","author":"Halld\u00f3rsd\u00f3ttir","year":"2011","journal-title":"Leukemia"},{"issue":"15","key":"2019111703273082300_B20","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.2016.70.7901","article-title":"New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111703273082300_B21","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N Engl J Med"},{"issue":"30","key":"2019111703273082300_B22","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1200\/JCO.2010.28.3945","article-title":"Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)","volume":"28","author":"Avet-Loiseau","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111703273082300_B23","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.13456","article-title":"Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed\/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial","volume":"170","author":"Goy","year":"2015","journal-title":"Br J Haematol"},{"issue":"22","key":"2019111703273082300_B24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood.V128.22.148.148","article-title":"Ibrutinib-lenalidomide-rituximab in patients with relapsed\/refractory mantle cell lymphoma: first results from the Nordic Lymphoma Group MCL6 (PHILEMON) phase II trial","volume":"128","author":"Jerkeman","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2019111703273082300_B25","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/blood.V128.22.610.610","article-title":"PIK3IP1 inhibition of PI3K in G1 arrest induced by CDK4 inhibition reprograms MCL for ibrutinib therapy","volume":"128","author":"Di Liberto","year":"2016","journal-title":"Blood"},{"issue":"10020","key":"2019111703273082300_B26","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"2019111703273082300_B27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.2013.49.2454","article-title":"Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality","volume":"32","author":"Fenske","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111703273082300_B28","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdt139","article-title":"Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network","volume":"24","author":"Cheah","year":"2013","journal-title":"Ann Oncol"},{"issue":"9","key":"2019111703273082300_B29","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.3109\/10428194.2013.767454","article-title":"Risk factors of central nervous system relapse in mantle cell lymphoma","volume":"54","author":"Conconi","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2019111703273082300_B30","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdv074","article-title":"Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL)","volume":"26","author":"Chihara","year":"2015","journal-title":"Ann Oncol"},{"issue":"5","key":"2019111703273082300_B31","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol"},{"issue":"22","key":"2019111703273082300_B32","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood.V128.22.783.783","article-title":"Single-agent ibrutinib in recurrent\/refractory central nervous system lymphoma","volume":"128","author":"Grommes","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2019111703273082300_B33","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood.V128.22.784.784","article-title":"Ibrutinib monotherapy in relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreo-retinal lymphoma (PVRL). Result of the interim analysis of the iLOC phase II study from the Lysa and the French LOC Network","volume":"128","author":"Choquet","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2019111703273082300_B34","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.V128.22.785.785","article-title":"Rituximab-lenalidomide (REVRI) in relapse or refractory primary central nervous system (PCNSL) or vitreo retinal lymphoma (PVRL): results of a \u201cproof of concept\u201d, phase II study of the French LOC Network","volume":"128","author":"Ghesquieres","year":"2016","journal-title":"Blood"},{"issue":"21","key":"2019111703273082300_B35","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1182\/blood.V124.21.4470.4470","article-title":"Interim results of a phase I study of lenalidomide (CC-5013) plus intraventricular\/intravenous rituximab for recurrent\/refractory CNS and intraocular lymphoma","volume":"124","author":"Rubenstein","year":"2014","journal-title":"Blood"},{"issue":"14","key":"2019111703273082300_B36","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1182\/blood-2015-05-647834","article-title":"Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse","volume":"126","author":"Bernard","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2019111703273082300_B37","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2019111703273082300_B38","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","article-title":"Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes","volume":"26","author":"Cheah","year":"2015","journal-title":"Ann Oncol"},{"key":"2019111703273082300_B39","article-title":"Predictive factors and outcomes for ibrutinib therapy in relapsed\/refractory mantle cell lymphoma\u2014a \u201creal world\u201d study [published online ahead of print 8 January 2017]","volume-title":"Hematol Oncol","author":"Epperla"},{"issue":"9","key":"2019111703273082300_B40","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov"},{"issue":"1","key":"2019111703273082300_B41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat Med"},{"issue":"22","key":"2019111703273082300_B42","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1182\/blood.V128.22.1786.1786","article-title":"Effectiveness of lenalidomide in patients with mantle cell lymphoma who relapsed\/progressed after or were refractory\/intolerant to ibrutinib: the MCL-004 Study","volume":"128","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"2019111703273082300_B43","article-title":"Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma [published online ahead of print 2 April 2017]","volume-title":"Br J Haematol","author":"Srour"},{"issue":"20","key":"2019111703273082300_B44","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/304\/1250486\/hem00042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2017\/1\/304\/1250486\/hem00042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,23]],"date-time":"2019-11-23T14:47:55Z","timestamp":1574520475000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2017\/1\/304\/21135\/Optimizing-therapy-for-mantle-cell-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,8]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2017.1.304","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,8]]}}}